Quantcast

Latest SLE Stories

2011-10-27 10:32:31

Atorvastatin is safe and may benefit pediatric patients with more severe lupus Atorvastatin therapy was found to be ineffective in reducing atherosclerosis progression in children and adolescents with systemic lupus erythematosus (SLE). Results of the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Trial, now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), report that the statin...

2011-05-26 14:57:19

Results of a Chinese study showed that the HPV vaccine did not have significant effects on the number of disease flares or antibody measures in patients with inactive SLE receiving stable doses of medications after administration, and therefore was determined safe to use to prevent HPV in this group of patients. SLE, an autoimmune disorder, affects nine times as many women as men and studies have shown that the rate of HPV in this group is significantly higher than in the healthy population....

2011-04-06 13:33:00

AWARDS AN ADDITIONAL $3.6 MILLION IN LUPUS RESEARCH, REACHING $5.6 MILLION IN 2010 NEW YORK, April 6, 2011 /PRNewswire-USNewswire/ -- The Alliance for Lupus Research (ALR) - the world's largest private funder of lupus research - today announced its most recent medical research grant awards, totaling $3.6 million, which support the ALR mission of finding better treatments and ultimately preventing and curing systemic lupus erythematosus (SLE, or lupus), a debilitating autoimmune disease....

2011-03-09 14:22:00

Alliance For Lupus Research Commits $500,000 To Glean Genetic Basis For Lupus In African Americans And Other Ethnicities Powerful ImmunoChip Technology Expands Range of Testing NEW YORK, March 9, 2011 /PRNewswire-USNewswire/ -- The Alliance for Lupus Research (ALR) - the world's largest private funder of lupus research - today announced funding of an important new study to identify lupus susceptibility genes in multiple ethnicities including African Americans, who are three times more...

2011-01-27 14:24:50

Activation of interferon signaling pathway may cause premature plaque build-up Researchers in China have demonstrated interferon-alpha (IFN-a) is associated with increased risk of atherosclerosis in patients with systemic lupus erythematosus (SLE). For the first time, IFN-a priming was shown to promote lipid uptake and foam cell formation"”a crucial step in plaque build-up. This activation of the IFN signaling pathway may be linked to the premature atherosclerosis risk in SLE. Full...

2010-12-31 12:20:16

(Ivanhoe Newswire) "“ A new study provides insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus (SLE). The research shows an unexpected role for a key type of immune cell could provide a potential new therapeutic strategy for SLE and, possibly, other autoimmune diseases. SLE is a chronic systemic disease that can affect many regions of the body and, as a result, presents with diverse clinical symptoms. As is characteristic of other...

2010-12-17 12:53:03

A new study provides fascinating insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus A new study provides fascinating insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus (SLE). The research, published by Cell Press in the December issue of the journal Immunity, reveals an unexpected role for a key type of immune cell and provides a potential new therapeutic strategy for SLE and,...

2010-11-09 07:05:00

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- UCB (EURONEXT: UCB) and U.S. based partner Immunomedics Inc. (Nasdaq: IMMU) announced that results from the phase IIb study, EMBLEM(TM), showed that certain doses of epratuzumab were associated with a meaningful and statistically significant* reduction in disease activity in adult patients with moderate to severe active SLE. The EMBLEM(TM) study was designed to evaluate the efficacy and safety of epratuzumab (in combination with immunosuppressants)...

2010-09-28 19:00:04

Further trials needed to determine clinical application of drug in SLE Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE). Abatacept failed to prevent new disease flares in SLE patients tapered from corticosteroids in an analysis where mild, moderate and severe disease flares were evaluated together. Full details of the phase IIb clinical trial are published in...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'